Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
Want to see FHTX full AI Analyst Report?
FHTX Stock Chart & Stats
$5.29
$0.09(1.92%)
At close: 4:00 PM EST
$5.29
$0.09(1.92%)
Day’s Range― - ―
52-Week Range$3.27 - $6.95
Previous CloseN/A
Volume24.60K
Average Volume (3M)157.41K
Market Cap
$245.42M
Enterprise Value$204.38M
Total Cash (Recent Filing)$184.88M
Total Debt (Recent Filing)$41.99M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 11, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding58,713,920
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue7.24
Enterprise Value/Gross Profit32.53
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$11.75Price Target Upside122.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.04
Revenue Forecast (FY)$25.52M
Bulls Say, Bears Say
Bulls Say
Pipeline Progress - FHD-909Ongoing Phase 1 progress and strong preclinical combo efficacy materially validate target biology and the company’s Gene Traffic Control platform. This de-risks the lead program, raises the probability of subsequent clinical success or partner-driven development, and supports durable scientific credibility.
Strategic Lilly Collaboration & CashA broad collaboration with Eli Lilly plus substantial cash reserves and recent financings extend runway and provide non-dilutive support and external validation. That structural funding and partnership reduce near-term execution risk and allow multiple IND-enabling programs to advance without immediate dependence on market capital raises.
Diversified Degrader PipelineMultiple degrader programs progressing toward IND-enabling work create several development pathways beyond the lead SMARCA2 program. This diversified R&D portfolio increases long-term upside, spreads clinical risk across targets and indications, and strengthens the firm’s positioning in chromatin-directed oncology.
Bears Say
Negative Stockholders' EquitySustained negative equity is a durable financial weakness that limits capital flexibility and can raise borrowing costs or restrict partnership terms. Over multiple periods this condition increases reliance on external financing and heightens dilution or covenant risk if clinical progress slows.
Persistent Cash BurnChronic negative operating and free cash flow indicate the business must secure ongoing external capital absent product revenue. This structural cash burn elevates dilution risk and ties the company’s sustainability to successful clinical readouts, partner payments, or frequent financings over the medium term.
Volatile Revenue & Weak MarginsIrregular revenue growth and a recent gross margin decline weaken operating leverage and lengthen the path to profitability. For a clinical-stage biotech, this structural margin pressure increases dependence on collaborator milestones and makes achieving sustainable commercial margins harder if multiple programs must be supported.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $3.27 and its highest was $6.95 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $245.42M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 56 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on May 07, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.305 by $0.015.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 58,713,920 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.305. Following the earnings report the stock price went down -10.256%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Foghorn Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (122.12% Upside)
$11.75 (122.12% Upside)
Hedge Fund Trend
Increased
By 904.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.32%
12-Months-Change
Fundamentals
Return on Equity
85.78%
Trailing 12-Months
Asset Growth
-14.12%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$11.75
▲(122.12% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
10.43% Mutual Funds
46.22% Other Institutional Investors
36.82% Public Companies and
Individual Investors